Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Analysts at Cantor Fitzgerald lifted their FY2018 earnings estimates for shares of Supernus Pharmaceuticals in a research report issued to clients and investors on Sunday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner now anticipates that the specialty pharmaceutical company will post earnings of $1.86 per share for the year, up from their previous estimate of $1.72. Cantor Fitzgerald also issued estimates for Supernus Pharmaceuticals’ FY2019 earnings at $3.05 EPS.
Several other equities research analysts have also commented on the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 8th. ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 target price for the company. B. Riley reissued a “buy” rating and set a $54.00 target price on shares of Supernus Pharmaceuticals in a research report on Thursday, January 18th. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $51.36.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The business’s revenue for the quarter was up 41.5% on a year-over-year basis.
In related news, VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $48.04, for a total transaction of $960,800.00. Following the completion of the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at $1,561,300. The disclosure for this sale can be found here. Insiders have sold a total of 165,750 shares of company stock valued at $7,133,973 over the last three months. Insiders own 6.70% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Public Employees Retirement Association of Colorado bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $188,000. Elkfork Partners LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $217,000. Sigma Planning Corp bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $219,000. Parametrica Management Ltd bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $247,000. Finally, Quantbot Technologies LP bought a new position in Supernus Pharmaceuticals in the 3rd quarter worth approximately $248,000. 96.31% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for Supernus Pharmaceuticals Inc Boosted by Cantor Fitzgerald (SUPN)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2018/03/14/fy2018-earnings-estimate-for-supernus-pharmaceuticals-inc-issued-by-cantor-fitzgerald-supn.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.